|
 The drugmaker said on Wednesday the decision by the Food and Drug
Administration (FDA) reflected the potential of Brilinta to address
an unmet medical need by reducing risks for patients who had a heart
attack one to three years previously.
The FDA grants a priority review when a medicine has scope to
provide significant improvements in the treatment.
AstraZeneca is relying on Brilinta, which it believes can sell $3.5
billion annually by 2023, to help offset a wave of patent losses on
older drugs. The product was a central plank in its defense against
a takeover bid by Pfizer last year.
(Reporting by Ben Hirschler; editing by David Clarke)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
